Carcinoma, Ductal, Breast: An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.Carcinoma, Ductal: Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.Breast Neoplasms: Tumors or cancer of the human BREAST.Breast: In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES.Carcinoma, Intraductal, Noninfiltrating: A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Carcinoma in Situ: A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.Neoplasm Invasiveness: Ability of neoplasms to infiltrate and actively destroy surrounding tissue.Carcinoma, Lobular: A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)Receptor, erbB-2: A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Receptors, Estrogen: Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.Ki-67 Antigen: A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.Receptors, Progesterone: Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.Lymphatic Metastasis: Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.Gene Expression Regulation, Neoplastic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.Breast Diseases: Pathological processes of the BREAST.Cell Line, Tumor: A cell line derived from cultured tumor cells.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Cadherins: Calcium-dependent cell adhesion proteins. They are important in the formation of ADHERENS JUNCTIONS between cells. Cadherins are classified by their distinct immunological and tissue specificities, either by letters (E- for epithelial, N- for neural, and P- for placental cadherins) or by numbers (cadherin-12 or N-cadherin 2 for brain-cadherin). Cadherins promote cell adhesion via a homophilic mechanism as in the construction of tissues and of the whole animal body.Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Carcinoma, Papillary: A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)Immunoenzyme Techniques: Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.Metallothionein: A low-molecular-weight (approx. 10 kD) protein occurring in the cytoplasm of kidney cortex and liver. It is rich in cysteinyl residues and contains no aromatic amino acids. Metallothionein shows high affinity for bivalent heavy metals.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Liver Neoplasms: Tumors or cancer of the LIVER.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Breast Feeding: The nursing of an infant at the breast.Carcinoma, Basal Cell: A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Mammography: Radiographic examination of the breast.Fibrocystic Breast Disease: A common and benign breast disease characterized by varying degree of fibrocystic changes in the breast tissue. There are three major patterns of morphological changes, including FIBROSIS, formation of CYSTS, and proliferation of glandular tissue (adenosis). The fibrocystic breast has a dense irregular, lumpy, bumpy consistency.Breast Neoplasms, Male: Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.Pancreatic Ducts: Ducts that collect PANCREATIC JUICE from the PANCREAS and supply it to the DUODENUM.Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Nipples: The conic organs which usually give outlet to milk from the mammary glands.Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.Carcinoma, Medullary: A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Carcinoma, Adenoid Cystic: Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)Carcinoma, Bronchogenic: Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Mastectomy: Surgical procedure to remove one or both breasts.Carcinoma, Small Cell: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)Mice, Nude: Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.Lung Neoplasms: Tumors or cancer of the LUNG.Cell Proliferation: All of the processes involved in increasing CELL NUMBER including CELL DIVISION.Tamoxifen: One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.Carcinoma, Neuroendocrine: A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)DNA, Neoplasm: DNA present in neoplastic tissue.Reverse Transcriptase Polymerase Chain Reaction: A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.Mammary Neoplasms, Experimental: Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Mastectomy, Segmental: Removal of only enough breast tissue to ensure that the margins of the resected surgical specimen are free of tumor.Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.Nasopharyngeal Neoplasms: Tumors or cancer of the NASOPHARYNX.Adenocarcinoma, Mucinous: An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Precancerous Conditions: Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)Breast Implants: Implants used to reconstruct and/or cosmetically enhance the female breast. They have an outer shell or envelope of silicone elastomer and are filled with either saline or silicone gel. The outer shell may be either smooth or textured.Fibroadenoma: An adenoma containing fibrous tissue. It should be differentiated from ADENOFIBROMA which is a tumor composed of connective tissue (fibroma) containing glandular (adeno-) structures. (From Dorland, 27th ed)Disease Progression: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.Case-Control Studies: Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Carcinoma, Adenosquamous: A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.Breast Self-Examination: The inspection of one's breasts, usually for signs of disease, especially neoplastic disease.Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Neoplasms, Multiple Primary: Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.Mammary Glands, Human: Glandular tissue in the BREAST of human that is under the influence of hormones such as ESTROGENS; PROGESTINS; and PROLACTIN. In WOMEN, after PARTURITION, the mammary glands secrete milk (MILK, HUMAN) for the nourishment of the young.Tissue Array Analysis: The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Neoplasm Transplantation: Experimental transplantation of neoplasms in laboratory animals for research purposes.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Carcinoma, Mucoepidermoid: A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)Mammary Glands, Animal: MAMMARY GLANDS in the non-human MAMMALS.Apoptosis: One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.Ultrasonography, Mammary: Use of ultrasound for imaging the breast. The most frequent application is the diagnosis of neoplasms of the female breast.Tumor Suppressor Protein p53: Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.Gene Expression Profiling: The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)Colonic Neoplasms: Tumors or cancer of the COLON.Carcinoma, Endometrioid: An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.Cell Division: The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Genes, BRCA1: A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human CHROMOSOME 17 at locus 17q21. Mutations of this gene are associated with the formation of HEREDITARY BREAST AND OVARIAN CANCER SYNDROME. It encodes a large nuclear protein that is a component of DNA repair pathways.Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.Antineoplastic Agents, Hormonal: Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)Chemotherapy, Adjuvant: Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.Carcinoma, Embryonal: A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)Mouth Neoplasms: Tumors or cancer of the MOUTH.Keratins: A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.Carcinoma, Merkel Cell: A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)Mutation: Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.Signal Transduction: The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.Epithelial Cells: Cells that line the inner and outer surfaces of the body by forming cellular layers (EPITHELIUM) or masses. Epithelial cells lining the SKIN; the MOUTH; the NOSE; and the ANAL CANAL derive from ectoderm; those lining the RESPIRATORY SYSTEM and the DIGESTIVE SYSTEM derive from endoderm; others (CARDIOVASCULAR SYSTEM and LYMPHATIC SYSTEM) derive from mesoderm. Epithelial cells can be classified mainly by cell shape and function into squamous, glandular and transitional epithelial cells.Blotting, Western: Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.Biopsy: Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.RNA, Neoplasm: RNA present in neoplastic tissue.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Skin Neoplasms: Tumors or cancer of the SKIN.Carcinoma, Signet Ring Cell: A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.Adrenocortical Carcinoma: A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.Genes, erbB-2: The erbB-2 gene is a proto-oncogene that codes for the erbB-2 receptor (RECEPTOR, ERBB-2), a protein with structural features similar to the epidermal growth factor receptor. Its name originates from the viral oncogene homolog (v-erbB) which is a truncated form of the chicken erbB gene found in the avian erythroblastosis virus. Overexpression and amplification of the gene is associated with a significant number of adenocarcinomas. The human c-erbB-2 gene is located at 17q21.2.Stomach Neoplasms: Tumors or cancer of the STOMACH.Carcinoma, Verrucous: A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, esophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months. (Segen, Dictionary of Modern Medicine, 1992)Transplantation, Heterologous: Transplantation between animals of different species.Estrogen Receptor alpha: One of the ESTROGEN RECEPTORS that has marked affinity for ESTRADIOL. Its expression and function differs from, and in some ways opposes, ESTROGEN RECEPTOR BETA.Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Neoplasm Grading: Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.Estrogens: Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds.Kaplan-Meier Estimate: A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)Axilla: Area of the human body underneath the SHOULDER JOINT, also known as the armpit or underarm.Uterine Cervical Neoplasms: Tumors or cancer of the UTERINE CERVIX.Lymph Nodes: They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.Postmenopause: The physiological period following the MENOPAUSE, the permanent cessation of the menstrual life.Pancreas: A nodular organ in the ABDOMEN that contains a mixture of ENDOCRINE GLANDS and EXOCRINE GLANDS. The small endocrine portion consists of the ISLETS OF LANGERHANS secreting a number of hormones into the blood stream. The large exocrine portion (EXOCRINE PANCREAS) is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the DUODENUM.Drug Resistance, Neoplasm: Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.Mammaplasty: Surgical reconstruction of the breast including both augmentation and reduction.Mucin-1: Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.Biopsy, Needle: Removal and examination of tissue obtained through a transdermal needle inserted into the specific region, organ, or tissue being analyzed.Gene Amplification: A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication.Multivariate Analysis: A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.Carcinoma, Large Cell: A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)Incidence: The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.Predictive Value of Tests: In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.Loss of Heterozygosity: The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.Oligonucleotide Array Sequence Analysis: Hybridization of a nucleic acid sample to a very large set of OLIGONUCLEOTIDE PROBES, which have been attached individually in columns and rows to a solid support, to determine a BASE SEQUENCE, or to detect variations in a gene sequence, GENE EXPRESSION, or for GENE MAPPING.Cohort Studies: Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.Salivary Ducts: Any of the ducts which transport saliva. Salivary ducts include the parotid duct, the major and minor sublingual ducts, and the submandibular duct.Tumor Suppressor Proteins: Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.Prospective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Mastectomy, Modified Radical: Total mastectomy with axillary node dissection, but with preservation of the pectoral muscles.Gene Expression: The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.Base Sequence: The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.Genes, Tumor Suppressor: Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.Receptor, Epidermal Growth Factor: A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.Tumor Burden: The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.Genes, p53: Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53.Laryngeal Neoplasms: Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.Genetic Predisposition to Disease: A latent susceptibility to disease at the genetic level, which may be activated under certain conditions.In Situ Hybridization, Fluorescence: A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.Adenofibroma: A benign neoplasm composed of glandular and fibrous tissues, with a relatively large proportion of glands. (Stedman, 25th ed)Epithelium: One or more layers of EPITHELIAL CELLS, supported by the basal lamina, which covers the inner or outer surfaces of the body.Down-Regulation: A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.Genes, BRCA2: A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human chromosome 13 at locus 13q12.3. Mutations in this gene predispose humans to breast and ovarian cancer. It encodes a large, nuclear protein that is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev 2000;14(11):1400-6)Apocrine Glands: Large, branched, specialized sweat glands that empty into the upper portion of a HAIR FOLLICLE instead of directly onto the SKIN.Neovascularization, Pathologic: A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.Radiotherapy, Adjuvant: Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.Age Factors: Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.Xenograft Model Antitumor Assays: In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.Keratin-5: A type II keratin that is found associated with the KERATIN-14 in the internal stratified EPITHELIUM. Mutations in the gene for keratin-5 are associated with EPIDERMOLYSIS BULLOSA SIMPLEX.Ductus Arteriosus: A fetal blood vessel connecting the pulmonary artery with the descending aorta.Cell Movement: The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell.Transfection: The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.Menopause: The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.Keratin-6: A type II keratin found associated with KERATIN-16 or KERATIN-17 in rapidly proliferating squamous epithelial tissue. Mutations in gene for keratin-6A and keratin-6B have been associated with PACHYONYCHIA CONGENITA, TYPE 1 and PACHYONYCHIA CONGENITA, TYPE 2 respectively.Adenocarcinoma, Follicular: An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.RNA, Small Interfering: Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.Proportional Hazards Models: Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.Risk Assessment: The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)BRCA2 Protein: A large, nuclear protein, encoded by the BRCA2 gene (GENE, BRCA2). Mutations in this gene predispose humans to breast and ovarian cancer. The BRCA2 protein is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev. 2000;14(11):1400-6)Premenopause: The period before MENOPAUSE. In premenopausal women, the climacteric transition from full sexual maturity to cessation of ovarian cycle takes place between the age of late thirty and early fifty.Breast Cyst: A fluid-filled closed cavity or sac that is lined by an EPITHELIUM and found in the BREAST. It may appear as a single large cyst in one breast, multifocal, or bilateral in FIBROCYSTIC BREAST DISEASE.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.BRCA1 Protein: The phosphoprotein encoded by the BRCA1 gene (GENE, BRCA1). In normal cells the BRCA1 protein is localized in the nucleus, whereas in the majority of breast cancer cell lines and in malignant pleural effusions from breast cancer patients, it is localized mainly in the cytoplasm. (Science 1995;270(5237):713,789-91)Transcription Factors: Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.MCF-7 Cells: An estrogen responsive cell line derived from a patient with metastatic human breast ADENOCARCINOMA (at the Michigan Cancer Foundation.)Up-Regulation: A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.Promoter Regions, Genetic: DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes.Neoplasms, Hormone-Dependent: Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.Milk, HumanNeoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Reproducibility of Results: The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results.Gallbladder Neoplasms: Tumors or cancer of the gallbladder.Neoadjuvant Therapy: Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.Therapeutic Irrigation: The washing of a body cavity or surface by flowing water or solution for therapy or diagnosis.Salivary Gland Neoplasms: Tumors or cancer of the SALIVARY GLANDS.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Embryonal Carcinoma Stem Cells: The malignant stem cells of TERATOCARCINOMAS, which resemble pluripotent stem cells of the BLASTOCYST INNER CELL MASS. The EC cells can be grown in vitro, and experimentally induced to differentiate. They are used as a model system for studying early embryonic cell differentiation.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Adenocarcinoma, Papillary: An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)Carcinoma, Non-Small-Cell Lung: A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.Carcinoma, Acinar Cell: A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)Phenotype: The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.Mass Screening: Organized periodic procedures performed on large groups of people for the purpose of detecting disease.Carcinoma, Papillary, Follicular: A thyroid neoplasm of mixed papillary and follicular arrangement. Its biological behavior and prognosis is the same as that of a papillary adenocarcinoma of the thyroid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1271)Mice, Inbred BALB C

Characterization of human MMTV-like (HML) elements similar to a sequence that was highly expressed in a human breast cancer: further definition of the HML-6 group. (1/2323)

Previously, we found a retroviral sequence, HML-6.2BC1, to be expressed at high levels in a multifocal ductal breast cancer from a 41-year-old woman who also developed ovarian carcinoma. The sequence of a human genomic clone (HML-6.28) selected by high-stringency hybridization with HML-6.2BC1 is reported here. It was 99% identical to HML-6.2BC1 and gave the same restriction fragments as total DNA. HML-6.28 is a 4.7-kb provirus with a 5'LTR, truncated in RT. Data from two similar genomic clones and sequences found in GenBank are also reported. Overlaps between them gave a rather complete picture of the HML-6.2BC1-like human endogenous retroviral elements. Work with somatic cell hybrids and FISH localized HML-6.28 to chromosome 6, band p21, close to the MHC region. The causal role of HML-6.28 in breast cancer remains unclear. Nevertheless, the ca. 20 Myr old HML-6 sequences enabled the definition of common and unique features of type A, B, and D (ABD) retroviruses. In Gag, HML-6 has no intervening sequences between matrix and capsid proteins, unlike extant exogenous ABD viruses, possibly an ancestral feature. Alignment of the dUTPase showed it to be present in all ABD viruses, but gave a phylogenetic tree different from trees made from other ABD genes, indicating a distinct phylogeny of dUTPase. A conserved 24-mer sequence in the amino terminus of some ABD envelope genes suggested a conserved function.  (+info)

Spectral morphometric characterization of breast carcinoma cells. (2/2323)

The spectral morphometric characteristics of standard haematoxylin and eosin breast carcinoma specimens were evaluated by light microscopy combined with a spectral imaging system. Light intensity at each wavelength in the range of 450-800 nm was recorded for 10(4) pixels from each field and represented as transmitted light spectra. A library of six characteristic spectra served to scan the cells and reconstruct new images depicting the nuclear area occupied by each spectrum. Fifteen cases of infiltrating ductal carcinoma and six cases of lobular carcinoma were examined; nine of the infiltrating ductal carcinoma and three of the lobular carcinoma showed an in situ component. The spectral morphometric analysis revealed a correlation between specific patterns of spectra and different groups of breast carcinoma cells. The most consistent result was that lobular carcinoma cells of in situ and infiltrating components from all patients showed a similar spectral pattern, whereas ductal carcinoma cells displayed spectral variety. Comparison of the in situ and the infiltrating ductal solid, cribriform and comedo carcinoma cells from the same patient revealed a strong similarity of the spectral elements and their relative distribution in the nucleus. The spectrum designated as number 5 in the library incorporated more than 40% of the nuclear area in 74.08% of the infiltrating lobular cells and in 13.64% of the infiltrating ductal carcinoma cells (P < 0.001). Spectrum number 2 appeared in all infiltrating ductal cells examined and in none of the lobular cells. These results indicate that spectrum number 5 is related to infiltrating lobular carcinoma, whereas spectrum number 2 is characteristic for infiltrating ductal carcinoma cells. Spectral similarity mapping of central necrotic regions of comedo type in situ carcinoma revealed nuclear fragmentation into defined segments composed of highly condensed chromatin. We conclude that the spectral morphometric features found for lobular and ductal cell populations may serve future automated histological diagnostics.  (+info)

Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. (3/2323)

We have previously reported that loss of p53 tumor suppressor protein results in centrosome hyperamplification, which leads to aberrant mitosis and chromosome instability. Since p53 is either deleted or mutated in human cancers at a high frequency, we investigated whether human cancers showed centrosome hyperamplification. Screening of advanced stage breast ductal carcinomas and squamous cell carcinomas of the head and neck (SCCHN) revealed that centrosome hyperamplification is frequent in both tumor types. Moreover, through the analyses of p53 in SCCHN samples by direct sequencing and by loss-of-heterozygosity test, we found that p53 mutations correlated with occurrence of centrosome hyperamplification. However, in some cases, we observed centrosome hyperamplification in tumors that retained wild-type p53. These tumors contained high levels of Mdm2. Since Mdm2 can inactivate p53 through physical association, we investigated whether Mdm2 overexpression induced centrosome hyperamplification. We found that Mdm2 overexpression, like loss of p53, induced centrosome hyperamplification and chromosome instability in cultured cells.  (+info)

Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. (4/2323)

CD40 is present on B cells, monocytes, dendritic cells, and endothelial cells, as well as a variety of neoplastic cell types, including carcinomas. CD40 stimulation by an antibody has previously been demonstrated to induce activation-induced cell death in aggressive histology human B-cell lymphoma cell lines. Therefore, we wanted to assess the effects of a recombinant soluble human CD40 ligand (srhCD40L) on human breast carcinoma cell lines. Human breast carcinoma cell lines were examined for CD40 expression by flow cytometry. CD40 expression could be detected on several human breast cancer cell lines and this could be augmented with interferon-gamma. The cell lines were then incubated with a srhCD40L to assess effects on in vitro growth. srhCD40L significantly inhibited the proliferation of the CD40(+) human breast cancer cell lines. This inhibition could also be augmented with interferon-gamma. Viability was also affected and this was shown to be due to increased apoptosis of the cell lines in response to the ligand. Treatment of tumor-bearing mice was then performed to assess the in vivo efficacy of the ligand. Treatment of tumor-bearing SCID mice with the ligand resulted in significant increases in survival. Thus, CD40 stimulation by its ligand directly inhibits human breast carcinoma cells in vitro and in vivo. These results suggest that srhCD40L may be of clinical use to inhibit human breast carcinoma growth.  (+info)

Induction of mammary carcinomas by N-methyl-N-nitrosourea in ovariectomized rats treated with epidermal growth factor. (5/2323)

The importance of epidermal growth factor (EGF) in both normal and malignant mammary gland development are presented in these studies. Initial findings demonstrated that in the absence of ovarian hormones, EGF had a significant proliferative effect on mammary epithelial cells. To determine whether mammary epithelial cells grown with EGF, in the absence of ovarian hormones, could be transformed by N-methyl-N-nitrosourea (MNU), female ovariectomized Lewis rats were implanted with pellets containing EGF for 1 week and then treated with MNU for initiation. Two days after MNU treatment, ovaries were implanted and EGF pellets were removed from all ovariectomized groups in order to promote carcinogenesis. The mammary carcinoma incidence of the EGF-stimulated group (90%) was not significantly different from the intact group (100%). The mammary cancer morphology of EGF-treated carcinomas was either ductal carcinoma or cribriform adenocarcinoma, whereas intact animals developed mainly papillary and occasional cribriform carcinomas. Fifty-eight percent of the carcinomas from the EGF group were ovarian hormone-independent compared with 10% of carcinomas from the intact group. These results demonstrate that EGF-induced proliferation during initiation with MNU was sufficient to induce the transformation of mammary carcinomas in the absence of ovarian hormones. The hormonal dependency of these EGF-induced carcinomas were different compared with MNU-initiated mammary carcinomas in intact rats.  (+info)

Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. (6/2323)

A centrosomal serine/threonine kinase, AIK1(3)/breast tumor amplified kinase/aurora2, which was recently identified as an oncogene, shows high amino acid identity with chromosome segregation kinases, fly Aurora, and yeast Ipl1. Immunohistochemical analyses of invasive ductal adenocarcinomas of the breast revealed that overexpression of AIK1 was observed in 94% of the cases, irrespective of the histopathological type, whereas the protein was not detected in normal ductal and lobular cells. Benign breast lesions including fibrocystic disease and fibroadenoma (epithelial components) displayed weakly detectable AIK1 expression in part of the lesions. This is the first immunohistochemical report of AIK1 expression in primary human breast carcinomas. Although the physiological function(s) of AIK1 kinase during cell division remains to be determined, the markedly high positivity of AIK1 staining in the cancer lesions suggested a possible involvement of its overexpression in the tumorigenesis of some of breast cancer cells.  (+info)

The influence of margin width on local control of ductal carcinoma in situ of the breast. (7/2323)

BACKGROUND: Ductal carcinoma in situ is a non-invasive carcinoma that is unlikely to recur if completely excised. Margin width, the distance between the boundary of the lesion and the edge of the excised specimen, may be an important determinant of local recurrence. METHODS: Margin widths, determined by direct measurement or ocular micrometry, and standardized evaluation of the tumor for nuclear grade, comedonecrosis, and size were performed on 469 specimens of ductal carcinoma in situ from patients who had been treated with breast-conserving surgery with or without postoperative radiation therapy, according to the choice of the patient or her physician. We analyzed the results in relation to margin width and whether the patient received postoperative radiation therapy. RESULTS: The mean (+/-SE) estimated probability of recurrence at eight years was 0.04+/-0.02 among 133 patients whose excised lesions had margin widths of 10 mm or more in every direction. Among these patients there was no benefit from postoperative radiation therapy. There was also no statistically significant benefit from postoperative radiation therapy among patients with margin widths of 1 to <10 mm. In contrast, there was a statistically significant benefit from radiation among patients in whom margin widths were less than 1 mm. CONCLUSIONS: Postoperative radiation therapy did not lower the recurrence rate among patients with ductal carcinoma in situ that was excised with margins of 10 mm or more. Patients in whom the margin width is less than 1 mm can benefit from postoperative radiation therapy.  (+info)

Prospective sonographic study of 3093 breast tumors. (8/2323)

To evaluate the predictive ability of sonographic tumor characteristics to differentiate benign from malignant tumors, we examined 3093 breast tumors (2360 benign and 733 malignant tumors) with ultrasonography. The ratio of the longest dimension to the anteroposterior diameter of benign tumors was significantly larger than that of malignant tumors (1.88+/-0.1 versus 1.69+/-0.02, P < 0.0001). Shape, margins, echogenicity, internal echo pattern, retrotumor acoustic shadowing, compressibility, and microcalcification were significant factors in the logistic regression model. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of breast sonography for malignancy were 86.1, 66.1, 44.1, 93.9, and 70.8%, respectively. Biopsy of the tumor for pathologic diagnosis is recommended if sonographic features are suggestive of malignancy.  (+info)

There is accumulating evidence to suggest that different histological grades of invasive ductal breast carcinomas may have distinct molecular origins and pathogenesis and do not typically progress from one grade group to another (28, 29, 30, 31) . The different grades have different clinical behaviors, and within-grade studies to identify the more aggressive subgroups of these classes of breast tumors would be of great assistance in clinical management. The expression of basal/myoepithelial markers has been observed in a proportion of grade III invasive breast tumors, and the spectrum of basal-like tumors, also recognized by morphology (15 , 32) , molecular cytogenetics (16 , 33) , and expression profiling (18 , 19) , has been associated with poor prognosis (17) . CGH has the advantage of being applied to archival pathology specimens with long-term follow-up as well as being amenable to microdissection strategies to profile the molecular genetic change occurring in a pure population of tumor ...
Gentaur molecular products has all kinds of products like :search , US Biomax \ Breast invasive ductal carcinoma tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 6 cases_24 cores, replacing BR243 \ BR243a for more molecular products just contact us
Gentaur molecular products has all kinds of products like :search , US Biomax \ Breast invasive ductal carcinoma with matched or unmatched adjacent normal breast tissue array, including TNM and pathology grade, 47cases_80cores, replacing BR802 \ BR802b for more molecular products just contact us
Jin, R.,Bay, B.H.,Chow, V.T.K.,Tan, P.H.,Lin, V.C.L. (2000). Metallothionein 1E mRNA is highly expressed in oestrogen receptor-negative human invasive ductal breast cancer. British Journal of Cancer 83 (3) : 319-323. [email protected] Repository ...
Mas pin is a se rine p rotease inhibito r with tumo r-su p p resso r activity. Mas pin can su p p ress tumo r g rowth and metastasis in vivo and tumo r cell motility and invasion in vit ro. P revious
PURPOSE: Information on tubular carcinoma (TC) of breast is limited due to its rarity. A multi-institutional study was performed to investigate the prognosis and failure patterns of TC compared to invasive ductal carcinoma (IDC). MATERIALS AND METHODS: We collected retrospective data on 205 patients with TC from eleven institutions. For each TC case, 3 cases with IDC were matched according to similar size, t-stage, and n-stage from the same institution. Patterns of failure, disease free survival (DFS) and overall survival (OS) were assessed and compared between the groups. RESULTS: DFS at 5 years was 98.8% and 97.3% and OS at 5 years was 99.5% and 99.6% in TC and IDC, respectively. Among the patients with TC, 5 patients (2.4%) developed contralateral breast cancer, while 3 patients (0.5%) presented with contralateral breast cancer in patients with IDC. CONCLUSIONS: The TC of breast presents an excellent prognosis, but the contralateral breast cancer tends to be more frequently observed compared ...
Mai, K. T., Perkins, D. G. and Mirsky, D. (2003), Location and Extent of Positive Resection Margins and Ductal Carcinoma in Situ in Lumpectomy Specimens of Ductal Breast Carcinoma Examined with a Microscopic Three-Dimensional View. The Breast Journal, 9: 33-38. doi: 10.1046/j.1524-4741.2003.09108.x ...
New research from Amsterdam shows that women over the age of 50 who have been diagnosed with ductal carcinoma in situ have a higher chance of being alive ten years after their diagnosis than women in the general population, according to Science Daily. Ductal carcinoma in situ is considered a disease separate from breast cancer because it is at stage 0 and does not spread around the body. However, ductal carcinoma in situ can progress into full-blown breast cancer, which is why it is still treated with surgery or surgery in combination with radiation therapy.. The researcher Dr. Lotte Elshof presented findings at the European Cancer Congress 2017. Women who have been diagnosed with ductal carcinoma in situ should feel better about their future because of these findings, which show their longevity will not be impacted by this condition.. Dr. Jelle Wesseling and her team at the Netherlands Cancer Institute followed approximately 10,000 Dutch women with ductal carcinoma in situ between the years ...
Invasive ductal carcinoma (IDC) is the most common form of breast cancer. Find out about IDC symptoms, diagnosis and treatment at Breast Cancer Care.
approximately three-quarters of breast cancers Invasive ductal carcinoma - 55% of breast cancers Ductal carcinoma in situ - 13% Invasive lobular carcinoma - 5% The overall 5-year survival rate for both ... Ductal carcinoma in situ, on the other hand, is in itself harmless, although if untreated approximately 60% of these low grade DCIS lesions will become invasive over the course of 40 years in follow-up ...
Invasive ductal carcinoma is the most commonly diagnosed breast cancer and has a tendency to metastasize via lymphatics. This lesion, which accounts for 75% of breast cancers, has no specific histolog... more
Background: Mounting evidence indicates that tumor-specific host immunity is associated with favorable prognosis in a variety of cancer settings. However, the role of immunity in breast cancer remains controversial. The purpose of this study was to determine the significance of tumor infiltrating leukocytes (TIL) with respect to pathological features and patient survival in estrogen receptor alpha (ER) negative breast cancer.. Patients and Methods: Tissue microarrays and immunohistochemistry were used to assess and categorize TIL in a cohort of 255 ER-negative invasive ductal breast carcinomas. Cases were registered by the Manitoba Breast Tumor Bank during the years 1988 to 2000 and had a minimum follow-up of 36 months. Stromal and intraepithelial TIL expressing the markers CD3, CD8, CD4, TIA1, CD25, FOXP3, CD20, CD68, and myeloperoxidase (MPO) were quantified by an experienced pathologist (PHW) and evaluated for associations with pathological parameters and survival. The median value for each ...
Hello, I was recently diagnozed with Invasive Ductal Carcinoma. I am 26 years old and this was such a shock to me and my husband. There are really no support groups in my area and I would love to hear from anyone going through this. ------------------------------------------------------------------------ This is an automatically-generated notice. If youd like to be removed from the mailing list, please visit the Medicine-On-Line Discussion Forum at ,http://www.meds.com/con_faq.html,, or send an email message to: [email protected] with the subject line blank and the body of the message containing the line: unsubscribe mol-cancer your-email-address where the phrase your-email-address is replaced with your actual email address ...
Purpose: The present study analyzed the polymorphisms of DNA repair genes and their impact on survival of patients with early breast cancer.Patients and methods: A total of 240 patients with surgically resected early invasive ductal breast cancer were enrolled in the present study, where patients who underwent neoadjuvant treatment were excluded. The genomic DNA was extracted from paraffin-embedded tumor-free tissue or blood, and thirteen single nucleotide polymorphisms of 12 DNA repair genes were determined using the Sequenom Mass array system.Results: Among the target SNPs, VARS2 rs2074511 and POLE rs5744857 were found to correlate with relapse-free survival (RFS) after curative surgery in the log-rank test. There was no difference in the clinical and tumor characteristics according to the genotypes of these two coding variants except for the higher incidence of positive ER in patients with the GG genotype of POLE rs5744857 (p = 0.025). Multivariate analysis showed that the GG genotype of ...
Invasive ductal carcinoma is the most common type of breast malignancy, with varying molecular features and resistance to treatment. Although CD44+/CD24- cells are believed to act as breast cancer stem cells and to be linked to poor prognosis in some patients, the association between these cells and tumor recurrence or metastasis in all or some types of invasive ductal carcinoma is unclear. A total of 147 randomly selected primary and secondary invasive ductal carcinoma samples were assayed for expression of CD44, CD24, ER, PR, and Her2. The association between the proportions of CD44+/CD24- tumor cells and the clinico-pathological features of these patients was evaluated. CD44+/CD24- tumor cells were detected in 70.1% of the tumors, with a median proportion of 5.8%. The proportion of CD44+/CD24- tumor cells was significantly associated with lymph node involvement (P = 0.026) and PR status (P = 0.038), and was correlated with strong PR status in patients with recurrent or metastatic tumors (P = 0.046)
Symptoms, diagnosis, treatment and prognosis for invasive ductal carcinoma-from the Johns Hopkins Breast Center in Baltimore, MD. Also get info for medullary, mucinous, papillary and tubular ductal carcinomas.
Recent studies suggest an association between chronic inflammation, modulating the tissue microenvironment, and tumor biology. Tumor environment consists of tumor, stromal and endothelial cells and infiltrating macrophages, T lymphocytes, and dendritic cells, producing an array of cytokines, chemokines and growth factors, accounting for a complex cell interaction and regulation of differentiation, activation, function and survival of tumor and surrounding cells, responsible for tumor progression and spreading or induction of antitumor immune responses and rejection. Tumor Necrosis Factor (TNF) family members (19 ligands and 29 receptors) represent a pleiotropic family of agents, related to a plethora of cellular events from proliferation and differentiation to apoptosis and tumor reduction. Among these members, BAFF and APRIL (CD257 and CD256 respectively) gained an increased interest, in view of their role in cell protection, differentiation and growth, in a number of lymphocyte, epithelial and
Hollie Quinn suffered from the typical health complaints of an adult female; these included heartburn and acid reflux, along with painful cysts, vertigo and migraines.. Hollie says that she ate the typically American diet which was low in vegetables, high in sugar, and drank soda daily. She never questioned the health directives given to her by her doctors, and was never told that there might be a connection between her health issues and the diet that she was eating.. In 2002, when Hollie was just 27 years old and in her 38th week of pregnancy, she was diagnosed with an infiltrating ductal carcinoma. This is the most common type of breast cancer which affects some 80% of patients, and as its name suggests, the cancer had broken through the milk duct and was invading the surrounding tissues of the breast. Over time, invasive ductal carcinomas can spread to the lymph nodes and to other areas of the body. Hollies main tumor was 2.3 cm, with a second tumor measuring 0.6 cm. The larger tumor was a ...
In conclusion, Dr. Lori Pierce, Vice Provost for Academic and Faculty Affairs and Professor of Radiation Oncology at the University of Michigan, says "this article has summarized nicely the major challenges facing breast cancer patients and their physicians in the management of ductal carcinoma in situ (DCIS). DCIS is not an invasive disease but can progress to invasive breast cancer, and potentially impact survival, in a significant number of women if not adequately treated when diagnosed. And we know that for those patients treated with lumpectomy, radiation to follow will reduce the chance of DCIS returning and/or invasive disease developing by at least 50%. We also know, however, that in some patients, the likelihood that DCIS will progress to invasive disease is very low even in the absence of treatment. Unfortunately, we have not found a reproducible way to predict those who need to be treated and those who dont but many researchers are working on this very question. For now, clinicians ...
(KudoZ) English to Spanish translation of Metastatic Ductal Carcinoma of the Breast: carcinoma ductal metastásico de mama [Medical (general) (Medical)].
The most common type of invasive breast cancer. It begins in the lining of the milk ducts (thin tubes that carry milk from the lobules of the breast to the nipple) and spreads outside the ducts to surrounding normal tissue.
To compare the lesion distribution and the extent of the disease in ductal and lobular carcinomas of the breast, we studied 586 ductal and 133 lobular consecutive cancers. All cases were documented on large-format histology slides. The invasive component of ductal carcinomas was unifocal in 63.3% (371/586), multifocal in 35.5% (208/586), and diffuse in 1.2% (7/586) of the cases. The corresponding figures in the lobular group were 27.8% (37/133), 45.9% (61/586), and 26.3% (35/133), respectively. When the distribution of the in situ and invasive component in the same tumors was combined to give an aggregate pattern, the ductal carcinomas were unifocal in 41.6% (244/586), multifocal in 31.6% (185/586), and diffuse in 26.8% (157/586) of the cases. The corresponding figures in the lobular category were 15.0% (20/133), 54.2% (72/133), and 30.8% (41/133), respectively. Ductal cancers were extensive in 45.7% (268/586), lobular in 65.4% (87/133) of the cases. All these differences were statistically ...
The distribution of ductal carcinoma in situ DCIS grade in 4232 women and its impact on overdiagnosis in breast cancer screening. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
On July 23, 2008, I was diagnosed with bilateral breast cancer, invasive ductal carcinoma, Stage II, and ductal carcinoma in situ, Stage O. This blog was started to keep my family and friends connected during my surgery and treatment. This is my story!. ...
On July 23, 2008, I was diagnosed with bilateral breast cancer, invasive ductal carcinoma, Stage II, and ductal carcinoma in situ, Stage O. This blog was started to keep my family and friends connected during my surgery and treatment. This is my story!. ...
Mammography screening is deemed cost-effective for women aged 50-70. Yet the utilities informing breast screening policy are limited in their ability to adequately capture the benefits and risks. The evaluation of many cancer screening programmes present results in terms of cost per QALY but fail to include any disutility for the patients who have been over-diagnosed and may receive unnecessary treatment. This thesis presents an overview of the challenges associated with valuing breast cancer states, using the results of an empirical study deriving utilities from 172 women in Melbourne, Australia as an example of potential methods to capture the disutility of overtreatment. Ductal carcinoma in situ was used as a proxy to quantify the benefits and harms associated with the sequelae of screening. Utilities derived from 172 women for health states explicitly describing overdiagnosis were lower than those from the literature, where it is unlikely that women were informed that their treatment may ...
Queenie - Patient: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Currently in active treatment (initial surgery, receiving chemo rounds/radiation), Diagnosed: over 7 years ago, Female, Age: 74, Stage I
copland16 - Survivor: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Finished active treatment less than 5 years ago, Diagnosed: over 9 years ago, Female, Age: 48, Stage II, HER2 Positive: No, ER Positive: Yes, PR Positive: Yes
Rita - Patient: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Currently in active treatment (initial surgery, receiving chemo rounds/radiation), Diagnosed: almost 7 years ago, Female, Age: 50, Stage 0
penny364 - Survivor: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Finished active treatment less than 5 years ago, Diagnosed: about 5 years ago, Female, Age: 71, Stage 0, HER2 Positive: No, ER Positive: Yes, PR Positive: Yes
fortysomething - Survivor: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Finished active treatment less than 5 years ago, Diagnosed: over 11 years ago, Female, Age: 50
Patient: Breast Cancer > Invasive (Infiltrating) Ductal Carcinoma Patient Info: Living with cancer as a chronic illness (undergoing adjuvant therapy), Diagnosed: almost 16 years ago, Female, Age: 53, Stage III, HER2 Positive: Yes, ER Positive: No, PR Positive: No
MarcieB - Patient: Breast Cancer > Invasive (Infiltrating) Ductal Carcinoma Patient Info: Currently in active treatment (initial surgery, receiving chemo rounds/radiation), Diagnosed: over 1 year ago, Female, Age: 72, Stage II, HER2 Positive: Yes, ER Positive: Yes, PR Positive: Yes
Survivor: Breast Cancer > Invasive (Infiltrating) Ductal Carcinoma Patient Info: Finished active treatment less than 5 years ago, Diagnosed: almost 4 years ago, Female, Age: 47, Stage III, HER2 Positive: No, ER Positive: Yes, PR Positive: Yes
Dr. Ansanellis laser surgery serves as a tremendous benefit to a Ductal Carcinoma In Situ patient as it greatly reduces the chance of cancer cell spread.
Introduction Ductal carcinoma in situ (DCIS) is a common pre-invasive malignancy of the breast, representing approximately 20% of all breast cancer diagnoses...
HCC1395 BL is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as the breast carcinoma cell line HCC1395.  The cell line was initiated from a 43-year-old white female with a TNM stage I, grade 3 primary ductal carcinoma and a prior history of cancer; her mother had breast cancer.
RATIONALE: Diagnostic procedures, such as MRI, may help find ductal carcinoma in situ and find out how far the disease has spread.PURPOSE: This
Zamecnik, M. Atypical cystic lobules: an advancing edge of low-grade ductal carcinoma in situ?. Virchows Archiv 437, 469 (2000). https://doi.org/10.1007/s004280000253. Download ...
I recently was diagnosed with breast cancer...invasive ductal carcinoma. Absolutely no history of this in my family. Could there be a link between all the drugs for ms Ive taken and that?? Ive seen some posts on cop axons and ...
classification and prognostic scoring along with quantification of immune cells/mm [2] was performed. Data were entered and analyzed using SPSS version 16. Correlation of immune cell densities with various tumour sub-types was investigated using paired t-test and ANOVA. A p-value of ...
This is a case-based activity that includes discussion of a 36-year-old woman who originally presented at 18 weeks gestation with clinical T2N0, grade 3 invasive ductal carcinoma of the right breast. The tumor was ER+, PR+, and HER2 negative ...
When I was diagnosed with Invasive Ductal Carcinoma in 2015, I wanted my experience to have a purpose. I later celebrated my survivorship with a glamorous photo shoot, and felt other survivors could benefit from its psychological healing. PWCG helps patients wrap their heads around breast cancer, navigating them through treatment, side effects, and a "new normal". We celebrate survivorship, aiming to provide FREE glamorous photo shoots for up to 13 survivors a year. Your business with PWCG helps fund our mission. ...
荊 雪楓 , 覚道 健一 , 村上 真紀 , 中村 靖司 , 中村 美砂 , 横井 豊治 , 尾浦 正二 , 桜井 武男 ホルモンと臨牀 46, 157-166, 1998-09-30 医中誌Web 参考文献23件 ...
Established in 1995 from a primary ductal infiltrating breast carcinoma of a 50-year-old Caucasian woman; cells are described to be estrogen- and progesterone-receptor negative, and to possess a point mutation in p53 and a five-fold amplification of ...
Tie2/Tek expression in breast carcinoma: correlations of immunohistochemical assays and long-term follow-up in a series of 909 patients.: The degree of angiogen
Learning, knowledge, research, insight: welcome to the world of UBC Library, the second-largest academic research library in Canada.
Ductal carcinoma in situ is the fourth most common cancer diagnosis in women. Some say its not "really" cancer. But you wouldnt know that based on how it is treated.. by Sue Rochman ...
Epiteliul simplu pavimentos scuamos este alctuit din celule turtite papilar al dermului, n hipoderm, n corionul mucoaselor, n jurul organelor mobile dup hipertrofia i hiperplazia organului,in lunile la bovine si ecvine,cand splina.
Squamous cell carcinoma of the breast and its subtype, basal-human epidermal growth factor receptor 2 (HER2) phenotype, are very rare. Herein, we report a patient who developed recurrence of squamous cell carcinoma of the breast with basal-HER2 subtype 6 years after the initial diagnosis of invasive ductal carcinoma of the HER2 subtype. To the best of our knowledge, recurrence of invasive ductal carcinoma in the form of metaplastic squamous cell carcinoma of basal-HER2 subtype has not been reported previously. We present a pathological perspective of our experience ...
ConferenceSeries organizes Invasive Ductal Carcinoma national symposiums, conferences across the globe in association with popular Invasive Ductal Carcinoma associations and companies. OMICS group planned its conferences, and events in america, europe, middle east and asia pacific. locations which are popular with international conferences, symposiums and events are china, canada, dubai, uae, france, spain, india, australia, italy, germany, singapore, malaysia, brazil, south korea, san francisco, las vegas, san antonio, omaha, orlando, raleigh, santa clara, chicago, philadelphia, baltimore, united kingdom, valencia, dubai, beijing, hyderabad, bengaluru and mumbai
Gene expression profiling has taught us a great deal about the progression of fully-developed invasive breast cancer, and our study used this approach as a starting point to learn more about the progression of DCIS to invasive breast cancer. We are aware of at least 9 previous studies comparing expression between DCIS and invasive breast cancer, publishing results that can be compared with ours (8-16, 30). Collectively, these studies included 130 cases of DCIS and 126 of invasive breast cancer, which pales in comparison to previous expression profiling studies of invasive breast cancer alone involving thousands of cases. Our study increases the number of samples comparing DCIS to invasive breast cancer by about 50%, which is a helpful contribution given the relatively small numbers of cases overall addressing this important question.. A proportion of samples from this (17%) and the previous (37%) studies were paired DCIS and invasive breast cancer from the same breasts, which may not be the ...
AIMS--To determine if allelic loss on chromosomes 16q and 17p, commonly encountered in in situ and invasive ductal carcinomas, is present in atypical ductal hyperplasia (ADH); to determine whether ADH is a neoplastic (clonal) or hyperplastic (polyclonal) proliferation. METHODS--Fourteen cases of ADH were examined for allele loss at loci on chromosome 16q and 17p using a microdissection technique, polymorphic DNA markers and the polymerase chain reaction (PCR). RESULTS--Loss of heterozygosity (LOH) was detected in five of nine informative cases on chromosome 16q at the microsatellite D16S413 and two of eight informative cases on chromosome 17p at D17S796. CONCLUSIONS--The incidence of LOH at these loci is similar to that previously observed in ductal carcinoma in situ and in invasive ductal carcinoma. Because of the nature of the technique used, our findings also demonstrate that ADH is a monoclonal, and hence, neoplastic proliferation rather than a hyperplastic (polyclonal) condition as its name ...
Invasive lobular carcinoma (ILC), sometimes called infiltrating lobular carcinoma, is the second most common type of breast cancer after invasive ductal carcinoma. About 10% of all invasive breast cancers are invasive lobular carcinomas. Learn about the diagnosis and treatment of invasive lobular carcinoma.
Breastfeeding and Immunohistochemical Expression of ki-67, p53 and BCL2 in Infiltrating Lobular Breast Carcinoma. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Abstract: Background and Objectives: The initiating steps and precise pathway of breast tumorigenesis are poorly understood and it is unclear if Ductal Carcinoma In Situ (DCIS) progresses to invasive ductal carcinoma (IDCA) of the breast. This study was undertaken to identify proteins that are differentially expressed between IDCA and DCIS and that may predict the invasive potential of breast tumors. Methodology: It is utilized that the two-dimensional difference in gel electrophoresis technology (2D-DIGE) and tandem mass spectrometry (LC-MS/MS) to perform proteomic analysis of IDCA (MCF-7 and BT-474) and DCIS (HCC-1500 and HCC-38) cell lines. Results: Identified 10 proteins that were differentially expressed between IDCA and DCIS (≥2-fold difference; p≤0.05) and classified the proteins according to their Gene Ontology (GO). Out of these proteins, 60 kDa mitochondrial heat shock protein (HSPD1), Heat Shock Protein Beta 1 (HSPB1) and the voltage-dependent anion-selective channel protein 1 ...
Conducted in the three-county Seattle-Puget Sound metropolitan area, the population-based study included women ages 55 to 74 years: 880 of the women had invasive ductal breast cancer, 1,027 had invasive lobular breast cancer, and 856 of them had no cancer and served as the control group. Interviewing participants in person, researchers gathered in-depth histories of hypertension and heart disease, as well as risk factors for cancer, including family history, obesity, smoking, and alcohol use. Through a series of structured questions, the research also included detailed data regarding use of antihypertensive drugs, such as beginning and end dates of use, drug names, dose, route of administration, pattern of use, and indication ...
PHILADELPHIA - A recent report in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, adds to the growing evidence that fish oil supplements may play a role in preventing chronic disease. Researchers at the Fred Hutchinson Cancer Research Center in Seattle, Wash., led by Emily White, Ph.D., a member of the public health sciences division, asked 35,016 postmenopausal women who did not have a history of breast cancer to complete a 24-page questionnaire about their use of non-vitamin, non-mineral "specialty" supplements in the Vitamins and Lifestyle (VITAL) cohort study. After six years of follow-up, 880 cases of breast cancer were identified using the Surveillance, Epidemiology and End Results registry. Regular use of fish oil supplements, which contain high levels of the omega-3 fatty acids, EPA and DHA, was linked with a 32 percent reduced risk of breast cancer. The reduction in risk appeared to be restricted to invasive ductal breast cancer, ...
The Y-box-binding protein 1 (YB-1), a member of the cold-shock domain RNA-and DNA-binding protein family, has pleiotropic functions such as regulation of the cell cycle. The aim of this study was to evaluate if YB-1 is a proliferative marker in breast cancer and elucidate potential downstream targets involved in YB-1-mediated cell cycle regulation using RNA interference technology. YB-1 protein expression was evaluated in tissue microarrays of 131 breast invasive ductal carcinomas by immunohistochemistry, while the YB-1 gene expression profile was evaluated in the T-47D, MDA-MB-231, ZR-75-1 and MCF7 breast cancer cell lines. Silencing of the YB-1 gene in T-47D breast cancer cells was performed using siRNA and the effects of down-regulation of YB-1 on cell growth and regulation of the cell cycle were ascertained. A focused panel of 84 genes involved in cell cycle progression was also examined. In tissue microarrays, YB-1 expression was shown to be associated with proliferating cell nuclear ...
Ductal carcinoma in situ is a noninvasive precancer condition. The treatment resembles the treatment of invasive breast cancer. The aim of this exploratory study was to gain knowledge on the level of postoperative pain, sensory disturbances, and distress among a small group of Danish women with ductal carcinoma in situ who had sentinel lymph node biopsy in order to plan a population study. A subgroup of patients with ductal carcinoma in situ (n = 20) was compared to patients with invasive breast cancer (n = 455) at time of diagnosis and after 12 months. Six patients were interviewed on the impact of the diagnosis and life after treatment. We found no significant difference in reported sensory disturbances or pain after 12 months between the groups. More than one-third (39%) of ductal carcinoma in situ patients reported moderate to severe distress (≥ 7 on the Distress Thermometer) at time of diagnosis decreasing to 10% after 12 months. Similarly 36% of breast cancer patients reported distress ...
BACKGROUND: To investigate markers for predicting breast cancer progression, we performed a candidate gene-based study that assessed expression change of three genes, cyclin D1, β-catenin, and metastasis-associated protein-1 (MTA1), involving in aggressive phenotypes of cancerous cells, namely hyperproliferation, epithelial-mesenchymal transition, and global transcriptional regulation.. METHODS: Specimens were from 150 enrolled female patients, with invasive ductal carcinoma, followed up for more than 10 years. mRNA expression of cyclin D1, β-catenin, and MTA1 in cancerous and noncancerous cells microdissected from the primary tumor site was determined by quantitative real-time PCR. The relationship between mRNA expression levels of the genes and clinicopathologic features was assessed by statistical analysis. Disease-free and overall survival (DFS and OS) were analyzed by Kaplan-Meier analysis with log-rank test and a multivariate Cox regression model.. RESULTS: Cyclin D1 was shown to be ...
Lobular breast cancer, or invasive lobular carcinoma, starts out in the lobules, the glands that produce milk. Learn about symptoms, treatments, and more.
Sirolimus in Preventing Invasive Breast Cancer in Patients with Ductal Carcinoma In Situ, Lobular Carcinoma In Situ, Atypical Lobular Hyperplasia, or Atypical Ductal Hyperplasia - NCT02642094
Abstract Ductal carcinoma in situ (DCIS) is an intraductal neoplastic proliferation of epithelial cells that is separated from the breast stroma by an intact layer of basement membrane and myoepithelial cells. DCIS is a non-obligate precursor of invasive breast cancer, and up to 40% of these lesions progress to invasive disease if untreated. Currently, it is not possible to predict accurately which DCIS would be more likely to progress to invasive breast cancer as neither the significant drivers of the invasive transition have been identified, nor has the clinical utility of tests predicting the likelihood of progression been demonstrated. Although molecular studies have shown that qualitatively, synchronous DCIS and invasive breast cancers are remarkably similar, there is burgeoning evidence to demonstrate that intra-tumor genetic heterogeneity is observed in a subset of DCIS, and that the process of progression to invasive disease may constitute an evolutionary bottleneck, resulting in the ...
Aimée was diagnosed with Stage 2B/3A Invasive Ductal Breast Cancer. She was selected as a pro-bono candidate for proton therapy and had a very successful run with it, totaling six weeks. She recently graduated on April 13, and received her medal of honor in the form of a "challenge coin" engraved with her patient number, 891. The coin signifies her fight against cancer, so she can put this chapter of her life behind her ...
When a pathologist examines the tissue under a microscope, he or she looks for small clusters of tumor cells that appear to "float" in pools of mucin. The tumor may be made up mostly of mucin, or mostly of cancer cells separated by small amounts of mucin.. Mucinous carcinoma also can be found near, or mixed in with, other more common types of breast cancer. Sometimes a ductal carcinoma in situ (or DCIS, a cancer that has not spread outside the milk duct) is found near the mucinous carcinoma. A mucinous carcinoma also may have some areas within it that contain invasive ductal carcinoma cells. If the invasive ductal carcinoma cells make up more than 10% of the tumor, the cancer would be called a "mixed" mucinous carcinoma. A "pure" mucinous carcinoma means that at least 90-100% of the cells are mucinous.. Now or after surgery, the tissue should be tested for some other important features of a pure mucinous breast carcinoma:. ...
Our study found that a history of a clinical diagnosis of migraine is associated with a 26% reduced risk of breast cancer among both premenopausal and postmenopausal women. This result is consistent with the 33% reduction in risk of invasive ductal breast carcinomas observed in the only other published study to assess this relationship (1). In the data presented here, the association between migraine and breast cancer did not vary substantially by age at migraine diagnosis, but there was some suggestion that risks were lower among women who had used prescription migraine medications. Although we did not assess migraine severity, use of prescription medications may be a proxy for more severe disease, or this observation could also reflect a reduction in risk associated with use of these medications. The lack of a significant effect among women not using medication may also be the result of exposure misclassification because the proportion of women reporting a history of migraine who actually only ...
OS is a malignant tumor that occurs in bone tissues and mainly affects adolescents (16). Through developments in diagnostic and therapeutic techniques, the 5-year survival rate of patients with OS has increased by 60-70% in the last decade; however, the 20-year survival rate of patients with OS remains low, at ~20% (17,18). The mechanisms involved in the development of OS are largely unclear; thus, the identification of novel biomarkers in OS may be useful for future diagnosis and treatment of patients.. Dysregulated C-type lectins have been found in various diseases, including cancer (19,20). CLEC-2, a member of the C-type lectin family, was highly expressed in clear cell renal cell carcinoma and was positively associated with poor patient prognosis (21) and it was also observed to regulate cell proliferation and migration (22). CLEC3A, another C-type lectin, was reported to be highly expressed in breast invasive ductal carcinoma and promoted breast cancer cell proliferation and migration (8). ...
This is the first comprehensive study of MUC5AC immunoexpression in breast cancer. We detected MUC5AC expression in five of 68 cases, which included one pure colloid carcinoma (out of three cases) and four invasive ductal carcinomas (out of 65 cases). In a previous study, OConnell et al showed an altered pattern of mucin expression in mucinous (colloid) breast carcinomas.13 Using in situ hybridisation, these authors13 showed an increase of MUC2 and MUC5AC expression and a decrease of MUC1 expression in colloid breast carcinomas in comparison with non-colloid breast carcinomas. In the study of OConnell et al,13 MUC1 and MUC2 expression was studied by immunocytochemistry and in situ hybridisation, whereas the expression of MUC5AC was evaluated by in situ hybridisation alone. Our results reinforce their observations, showing that MUC5AC is overexpressed in some cases of colloid breast carcinoma. However, at variance with these authors13 we found that MUC5AC expression is not restricted to colloid ...
It is generally believed that atypical ductal hyperplasia (ADH) is a direct precursor of breast cancer and therefore portends breast cancer in the same breast, while atypical lobular hyperplasia (ALH) has an equal risk of cancer in both breasts and may not be a direct precursor of breast cancer. In the study, however, published in Cancer Prevention Research (2014;7;211-217) and led by Lynn C. Hartmann, MD, Professor of Oncology, cancer was twice as likely to occur in the breast having the biopsy, and this was true for both ADH and ALH.. Moreover, the findings run counter to current understanding that ALH primarily leads to lobular cancer. Instead, the researchers discovered that ALH was associated predominantly with later ductal cancers of the breast-also similar to cancers after ADH.. Both types resulted in invasive ductal cancers, and 69 percent were of intermediate or high grade. Further, about 25 percent had spread to the lymph nodes. Although the numbers were not statistically significant, ...
E-cadherin local dynamics were studied in mature junctions, that is, junctions engaged in adhesion for many hours, in which cadherin expression level ...
This multicentre retrospective study is characterised by a long period of accrual (median follow-up: 136 months,; range: 16-292 months), which offers the advantage of providing interesting information about the trend of the disease. A certain number of patients (12 patients) enrolled in the first years have died during this long period of observation; other patients (47 patients) didnt return for the planned examination to the Centre of Radiotherapy where they had been treated, and were lost to follow-up. In addition only approximately 20% of patients were treated in the first period (from 1985 to 1990) and the number of cases increased progressively during the following years (Figure 1). Most of the cases belong to the two decades covered by the screening activity. Nevertheless, a large number of cases were also found in the younger age group, between 41 and 50. Increased debate and publicity about breast cancer screening after the introduction of screening programmes could have determined an ...
Description of disease Breast, infiltrating lobular carcinoma of the. Treatment Breast, infiltrating lobular carcinoma of the. Symptoms and causes Breast, infiltrating lobular carcinoma of the Prophylaxis Breast, infiltrating lobular carcinoma of the
Hi. I did a search for Ductal Carcinoma and one of the hits was a letter from Jayna. I dont see anything else. Is there a web site I can go to? I would really like to find a lot more information about surgery, therapy and all alternatives. I know I am at the beginning of a long hard journey but I would like to give a little background which may help you point me in the right direction. I am 31 years old and back in August I found a lump. I spoke to my sister and a friend about it and both said wait a week or two to see if it would go away. I was a week away from my period so I waited. It did not go away. I called the OB/GYN and got an appointment for October 12th. I did not tell them about the lump, I guess I still figured it would go away. After I made the appointment I spoke to my mother, a breast cancer survivor twice. I told her the position of the lump and we both agreed that it was strange and would probably be nothing. Let me explain. My mother had breast cancer on the left side 11 years ...
Invasive lobular carcinoma has a much lower incidence than infiltrating ductal carcinoma, constituting less than 15% of cases of invasive breast cancer. It is characterized histologically by the &ldqu... more
The widespread adoption of screening mammography has led to an increase in the diagnosis of ductal carcinoma in situ (DCIS) of the breast. While it is estimated that 55,000 women in the US will be diagnosed with DCIS in 2013, only a small fraction of these women (~15%) will subsequently develop invasive breast cancer. However, most women with DCIS are treated as if they will develop invasive cancer. Almost a third of these women opt for a full mastectomy. In a majority of remaining women, the DCIS lesion is surgically excised with lumpectomy and, in over half of these women, additional radiation or tamoxifen treatment is provided. Thus, many women are receiving unnecessary adjuvant therapy to prevent invasive cancers that will not occur. Additionally, ~ 15% of women are not receiving adequate intervention because they will subsequently develop a subsequent invasive tumor even after receiving lumpectomy and adjuvant therapy. Identifying molecular markers that can accurately predict subsequent ...
TY - JOUR. T1 - A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease. AU - Jakub, James W. AU - Murphy, Brittany L.. AU - Gonzalez, Alexandra B.. AU - Conners, Amy L.. AU - Henrichsen, Tara L.. AU - Maimone, Santo IV. AU - Keeney, Michael G.. AU - McLaughlin, Sarah A.. AU - Pockaj, Barbara A. AU - Chen, Beiyun. AU - Musonza, Tashinga. AU - Harmsen, William S.. AU - Boughey, Judy C. AU - Hieken, Tina J. AU - Habermann, Elizabeth B. AU - Shah, Harsh N.. AU - Degnim, Amy C. PY - 2017/8/1. Y1 - 2017/8/1. N2 - Background: Approximately 8-56% of patients with a core needle biopsy (CNB) diagnosis of ductal carcinoma in situ (DCIS) will be upstaged to invasive disease at the time of excision. Patients with invasive disease are recommended to undergo axillary nodal staging, most often requiring a second operation. We developed and validated a nomogram to preoperatively predict percentage of risk for upstaging to invasive cancer. Methods: We reviewed 834 cases of DCIS ...
Objective: This study investigated whether gene expression levels of key modulators of the oxysterol signalling pathway modify the prognosis of patients with oestrogen receptor-positive (ER+) breast carcinomas via interaction with endocrine therapy. Context: The prognosis of patients with ER+ breast carcinoma depends on several factors. Previous studies have suggested that some oxygenated forms of cholesterol (oxysterols) bind to oestrogen receptor and anti-oestrogen binding site which may deregulate cholesterol homoeostasis and influence effect of therapy. Design: The expression levels of 70 oxysterol pathway genes were evaluated in a test set of breast carcinomas differing in ER expression. The genes differentially expressed in ER+ tumours were assessed in a comprehensive set of ER+ tumours to evaluate their clinical significance. Patients: A total of 193 primary patients with breast carcinoma were included. Measurements: The transcript levels were determined by quantitative real-time ...
Find the best invasive breast cancer doctors in Bangalore. Get guidance from medical experts to select invasive breast cancer specialist in Bangalore from trusted hospitals - credihealth.com
FRIDAY, Oct. 25, 2019 (HealthDay News) - For each month of delay between diagnosis and surgery for ductal carcinoma in situ (DCIS), there is slightly worse survival and an increase in risk for invasive disease, according to a study published online Sept. 27 in the Annals of Surgical Oncology.. William H. Ward, M.D., from Naval Medical Center in Portsmouth, Virginia, and colleagues used the National Cancer Database to identify women with a clinical diagnosis of DCIS between 2004 and 2014. Differences in overall survival (OS) and presence of invasion were compared for five intervals between diagnosis and surgery (≤30, 31 to 60, 61 to 90, 91 to 120, and 121 to 365 days).. The researchers identified 140,615 clinical DCIS patients, of whom 123,947 had pathologic diagnosis of DCIS and 16,668 had invasive ductal carcinoma. Overall, five-year OS was 95.8 percent, and unadjusted median delay from diagnosis to surgery was 38 days. There was a 7.4 percent increased relative risk for death for each ...
At Moffitt Cancer Center, breast cancer research is one of our primary areas of focus. Not only are we looking to determine how ductal carcinoma in situ develops, but also how it can be treated more effectively. For instance, we are studying various hormonal therapies and how they affect hormone receptor-positive cancers, using our laboratory advances to improve outcomes and quality of life for each of our patients.. Our expert oncologists can further explain the causes of ductal carcinoma in situ. To make an appointment, call 1-888-663-3488 or submit a new patient registration form online. No referral is required.. Helpful Links:. ...
After having a lumpectomy, chemo and radiation my wife is 2 1/2 years out from treatment and has a recurrence. She is scheduled for a mastectomy. What type of follow up treatment is availible? Her 1...
Ductal carcinoma in situ (DCIS) is a pre-invasive, early form of breast cancer. Find more about how DCIS is diagnosed and treated at Breast Cancer Now.
Initially diagnosed June 4, 2009 Invasive Ductal Carcinoma Stage II,Grade II tumor size: 2-3 cm node positive ER/PR postive HER2 Neu - negative Current Diagnosis: Metastatic Invasive Ductal Carcinoma Grade 3 Mets: Scalp/skin, Liver, Spine, Bone ER/PR + HER2/NEU ...
Background: Carcinoma of breast has become the major public health problem among females in developing as well as developed countries. InNepal it comprises 6% of total cancers cases and often diagnosed at advanced stage. Surgical removal or modified radical mastectomy (MRM) is the most commonly used tools for disease management. The objective of this study is to identify the clinical, macroscopic and microscopic features of MRM specimens.. Materials and methods: This prospective cross-sectional study was carried out at Department of Pathology, Bhaktapur Cancer Hospital, Bhaktapur, Nepal. Macroscopic and microscopic examination provided the tumor size, stage, grade, lymph node status, lympho-vascular invasion and perineural invasion. Data were collected and analyzed using SPSS 16.. Results: The study comprised 112 breast cancer patients of which 109 (97.3%) were females and 3 (2.7%) were males. Invasive ductal carcinoma no specific type was the most common type of breast carcinoma. (84 cases) ...
Breast cancer affects a large number of females in the Western world, accounting for half a million deaths worldwide on an annual basis. Carcinoma of the breast is a heterogeneous disease based on pathological criteria, which is probably due to the multiplicity of genetic lesions that have accumulated during tumor development, resulting in distinct tumor types. The most frequently observed subtypes, invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC), are very distinct phenotypically as well as biochemically (Coradini et al., 2002; Korkola et al., 2003; Mathieu et al., 2004; Zhao et al., 2004; Stange et al., 2006). ILC is a subtype of breast cancer that accounts for 10-15% of all cases and has a greater tendency for multifocal development and bilateral presentation than other primary breast tumors (Newstead et al., 1992; Krecke and Gisvold, 1993; Helvie et al., 1993). Classical ILC is characterized by non-cohesive invasive cells that are arranged in trabecules without mass ...
Get natural cures for Invasive Lobular Carcinoma that can make a difference in your life or the life of someone you love with alternative treatments.
Jones, C., Nonni, A. V., Fulford, L., Merrett, S., Chaggar, R., Eusebi, V., Lakhani, S. R. (2001) CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. BRITISH JOURNAL OF CANCER, 85 (3). pp. 422-427. ISSN 0007-0920 ...
ryan417 - Patient: Breast Cancer > Invasive (Infiltrating) Ductal Carcinoma Patient Info: Newly diagnosed (has not begun treatment), Diagnosed: over 7 years ago, Female, Age: 65, Stage I, HER2 Positive: Yes, ER Positive: Yes, PR Positive: Dont Know
Characteristics of lobular carcinoma and LCIS. Pictures showing the difference, and mentioning possible symptoms, mammogram findings and treatment.
Breast cancer is a disease in which certain cells in the breast become abnormal and multiply uncontrollably to form a tumor. Although breast cancer is much more common in women, this form of cancer can also develop in men. In both women and men, the most common form of breast cancer begins in cells lining the milk ducts (ductal cancer). In women, cancer can also develop in the glands that produce milk (lobular cancer). Most men have little or no lobular tissue, so lobular cancer in men is very rare.In its early stages, breast cancer usually does not cause pain and may exhibit no noticeable symptoms. As the cancer progresses, signs and symptoms can include a lump or thickening in or near the breast; a change in the size or shape of the breast; nipple discharge, tenderness, or retraction (turning inward); and skin irritation, dimpling, or scaliness. However, these changes can occur as part of many different conditions. Having one or more of these symptoms does not mean that a person definitely has ...
Breast cancer is a disease in which certain cells in the breast become abnormal and multiply uncontrollably to form a tumor. Although breast cancer is much more common in women, this form of cancer can also develop in men. In both women and men, the most common form of breast cancer begins in cells lining the milk ducts (ductal cancer). In women, cancer can also develop in the glands that produce milk (lobular cancer). Most men have little or no lobular tissue, so lobular cancer in men is very rare.In its early stages, breast cancer usually does not cause pain and may exhibit no noticeable symptoms. As the cancer progresses, signs and symptoms can include a lump or thickening in or near the breast; a change in the size or shape of the breast; nipple discharge, tenderness, or retraction (turning inward); and skin irritation, dimpling, or scaliness. However, these changes can occur as part of many different conditions. Having one or more of these symptoms does not mean that a person definitely has ...
Ductal carcinoma in situ (DCIS) occurs when some of the cells that line a group of milk ducts within your breast have started to become cancer cells.
Secretory breast carcinoma (SBC) is a very rare subtype of breast carcinoma that reported mostly in young women, with a median age of 25 years. Despite the low frequency, SBC elicits pathologic interest because of their unique morphology and excellent prognosis. Authors report a 23-year-old woman presented with a nodule in retro areolar region of her right breast. Microbiopsic examination revealed neoplastic tissue. Pathological examination of tumor revealed SBC. This tumor is morphologically characterized by the presence of abundant eosinophilic secretions in intracellular vacuoles and intercellular spaces. The objective of this paper is to review the epidemiological, clinical, paraclinical and therapeutic aspects of SBC from a case report and literature review.
Cutaneous adnexal tumour showing features of eccrine ductal differentiation that are characterized by a prominent squamoid component.. The tumours usually presents as solitary dermal nodules on the head and neck areas and the extremities in elderly patients.. Microscopic features: The tumour is characterized by a prominent squamous proliferation with atypia, keratinous cyst formation and squamous eddies which seem to merge with areas showing eccrine ductal differentiation, including ductular formations in continuity with eccrine ductal epithelium.. ...
The commonest form of breast cancer is ductal carcinoma, which begins while in the cells from the ducts. Breast cancer also can commence inside the cells from the lobules and in other tissues inside the breast. Ductal carcinoma in situ is usually a ailment by which abnormal cells are found in the lining of the ducts Nevertheless they havent unfold outside the house the duct ...
HCC1937BL is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as HCC1937 (a primary breast ductal carcinoma cell line, ATCC CRL-2336).
Cornfield D B, Schwartz G F, Shen R, McDade T, Kovatich A. (1996, May). Histologic and Immunohistochemical Features of Ductal Carcinoma In Situ of the Breast Recurring After Wide Excision Alone. Presentation presented at: 32nd annual Meeting of the American Soc Clinical Oncol, Philadelphia, PA.. ...
To review the ultrasound (US) patterns of pure ductal carcinoma in situ (DCIS) using a non-mass-like (NML) versus mass-like (ML) classification and to investigate histopathological associations....
I had a small lump in my breast that prompted me to Select a mammogram in February 2015. My final results came back again apparent, that it was just fibrous breast tissue. In Could I began getting Serovital HGH for that increased Vitality statements together with with the anti-getting older Qualities they claimed. I took these often from May well through November, having decided on a 6 thirty day period demo. By November, the lump in my breast experienced much more than doubled in size and had become Significantly more difficult. I went for an additional mammogram and an ultrasound by using a needle biopsy. It came back good. I had stage 2 invasive ductal carcinoma, with lymph node metastasis, which had all developed over a nine thirty day period period of time ...
Breast cancerEdit. Mastectomy specimen containing a very large cancer of the breast (in this case, an invasive ductal carcinoma ... Ductal carcinoma in situ (DCIS) breast cancerEdit. "DCIS patients and control subjects did not differ with respect to oral ... "What You Need To Know About Breast Cancer". National Cancer Institute.. *^ "Definite breast cancer risks". CancerHelp UK. ... Claus EB, Stowe M, Carter D (December 2001). "Breast carcinoma in situ: risk factors and screening patterns". Journal of the ...
... for invasive ductal carcinoma, or for other conditions. DCIS, or intraductal carcinoma, is by definition a breast cancer that ... "Ductal carcinoma in situ". Retrieved 19 March 2013. Additional Sources: Bleicher RJ. Ductal Carcinoma in Situ. Surg Clin N Am ... "Ductal carcinoma in situ". Retrieved 19 March 2013. Desantis C, Siegel R, Bandi P, et al. (2011). "Breast cancer statistics". ... "Sentinel lymph node biopsy in the management of ductal carcinoma in situ". Clin Breast Cancer. 6: 216-222. doi:10.3816/cbc.2005 ...
"IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland". Journal of ... produced by carcinoma cells, acts through paracrine signaling on endothelial cells and through autocrine signaling on carcinoma ... "Autocrine vascular endothelial growth factor signaling in breast cancer. Evidence from cell lines and primary breast cancer ... In HER2 overexpressing breast cancers, the HER2-IL-6-STAT3 signaling relationship could be targeted to develop new therapeutic ...
"The influence of margin width on local control of ductal carcinoma in situ of the breast". The New England Journal of Medicine ... "A prognostic index for ductal carcinoma in situ of the breast". Cancer. John Wiley & Sons. 77 (11): 2267-2274. doi:10.1002/( ... Lewinsky is a board certified radiation oncologist who is among the top 15% of breast cancer researchers in terms of ... Lewinsky has published a number of medical papers in collaboration with several other scientists that focus on breast cancer. ...
"Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast". Am. J ... of clear cell renal carcinomas. Two transcript variants encoding different isoforms have been identified for this gene. Loss of ... "Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau ...
... specimen containing a very large cancer of the breast (in this case, an invasive ductal carcinoma) ... large areas of ductal carcinoma in situ or even those persons that are removing the breast because of the possibility of breast ... an invasive ductal carcinoma of the breast, pale area at the center ... A mastectomy is usually carried out to treat breast cancer[1]. In some cases, people believed to be at high risk of breast ...
... removed from her left breast. The eventual diagnosis was "ductal carcinoma with medullary features".[not in citation given] Due ... "My Breast". New York Magazine. Is DNA Destiny? Utne Reader. March 1, 1998 My Breast by Joyce Wadler on Amazon.com "The Public ... Her memoir about breast cancer, My Breast: One Woman's Cancer Story (ISBN 0671017756; ISBN 978-0-671-01775-0) was originally a ... Wadler has been treated for both breast and ovarian cancer. In 1991, Wadler was diagnosed with breast cancer and had a ...
... lobular carcinoma in situ (LCIS) exhibits perinuclear staining with 34βE12. Ductal carcinoma in situ (DCIS) does not stain for ... Yeh IT, Mies C (March 2008). "Application of immunohistochemistry to breast lesions". Arch. Pathol. Lab. Med. 132 (3): 349-58. ... It can be used to differentiate in situ cancers of the breast; ...
2011). "Role of RNA binding protein HuR in ductal carcinoma in situ of the breast". The Journal of Pathology. 224: 529-539. doi ...
"Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type". The Journal of ... C11orf86 is down-regulated from non-neoplastic mucosa to adenomas and carcinomas, down-regulated in renal cell carcinoma, and ... and carcinomas". Experimental and Molecular Pathology. 90 (2): 201-209. doi:10.1016/j.yexmp.2010.12.004. Hidaka, Hiedo; Seki, ... aberrant expression and functional significance in renal cell carcinoma". Oncotarget. 3 (1): 44-57. doi:10.18632/oncotarget.417 ...
For example, the most common type of breast cancer is called ductal carcinoma of the breast. Here, the adjective ductal refers ... glioma Breast cancer Invasive lobular carcinoma Tubular carcinoma Invasive cribriform carcinoma Medullary carcinoma Male breast ... Nearly all cancers developing in the breast, prostate, lung, pancreas, and colon are carcinomas. Sarcoma: Cancers arising from ... cancer Phyllodes tumor Inflammatory Breast Cancer Adrenocortical carcinoma Islet cell carcinoma (endocrine pancreas) Multiple ...
ISBN 978-0-397-51624-7. Liong, Yee; Hong, Ga; Teo, Jennifer Gek; Lim, Geok (2013). "Breast ductal carcinoma in situ presenting ... Because it is so rare it may be sometimes confused with comedo carcinoma of the breast although the conditions appear to be ... Nonpuerperal breast abscesses have a higher rate of recurrence compared to puerperal breast abscesses. There is a high ... Often minor ductal and periductal inflammation is present. The lesion is in some cases very difficult to distinguish from ...
... gamma-tubulin in atypical ductal hyperplasia and carcinoma of the breast". Cancer Science. 100 (4): 580-7. doi:10.1111/j.1349- ...
For example, the most common type of breast cancer is called ductal carcinoma of the breast. Here, the adjective ductal refers ... An invasive ductal carcinoma of the breast (pale area at the center) surrounded by spikes of whitish scar tissue and yellow ... Radiation to the breast reduces the ability of that breast to produce milk and increases the risk of mastitis. Also, when ... for breast cancer, see Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, et al. (February 2009). "Breast ...
"Infiltrating ductal carcinoma breast with central necrosis closely mimicking ductal carcinoma in situ (comedo type): a case ... It is usually a type of ductal carcinoma in situ. Comedo carcinomas are usually non-infiltrating and intraductal tumors. ... ductal carcinoma. Recurrence and survival rates differ for invasive breast cancer which has originated as comedocarcinoma ... "Prognostic factors in ductal carcinoma in situ of the breast: results of a retrospective study of 575 cases". Eur J Obstet ...
Many genes which are grouped into clusters show the same expression profiles in human invasive ductal breast carcinomas. ... Brain and breast related genes didn't cluster. This shows that at least some clusters consist of functionally related genes. ...
... can be used to differentiate lobular carcinoma of the breast from ductal carcinoma of the breast. CAM 5.2, an antibody that ... such as spindle cell carcinoma. It is considered useful in identifying microscopic metastases of breast carcinoma in lymph ... October 2004). "Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients ... 1997). "A two-dimensional gel database of human colon carcinoma proteins". Electrophoresis. 18 (3-4): 605-13. doi:10.1002/elps. ...
"IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland". Journal of ... "Breast Cancer Research. 9 (5): R63. doi:10.1186/bcr1769. PMC 2242658. PMID 17897439.. ... "Autocrine vascular endothelial growth factor signaling in breast cancer. Evidence from cell lines and primary breast cancer ... In breast cancer, the acquisition of tamoxifen resistance is another major therapeutic problem. It has been shown that ...
"Microdissection and SAGE as a combined tool to reveal gene expression in ductal carcinoma in situ of the breast". Mol. Carcinog ... 2006). "Analysis of the candidate tumor suppressor Ris-1 in primary human breast carcinomas". Mutat. Res. 594 (1-2): 78-85. doi ...
Invasive ductal carcinomas of the breast often have a scirrhous, stellate appearance caused by desmoplastic formations. ... Walker, Rosemary A (2001). "The complexities of breast cancer desmoplasia". Breast Cancer Research. 3 (3): 143-5. doi:10.1186/ ... malignant melanoma Desmoplastic squamous cell carcinoma Morpheaform basal cell carcinoma Microcystic adnexal carcinoma ... 2011). "Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs". Nature Medicine. 17 (7 ...
2010). "[Diagnostic and prognostic significance of FOXA1 expression in molecular subtypes of breast invasive ductal carcinomas ... "Expression of FOXA1 and GATA-3 in breast cancer: The prognostic significance in hormone receptor-negative tumours". Breast ... FOXA1 in breast cancer is highly correlated with ERα+, GATA3+, and PR+ protein expression as well as endocrine signaling. FOXA1 ... 2009). "Up-regulation of the HSP72 by Foxa1 in MCF-7 human breast cancer cell line". Biochem. Biophys. Res. Commun. 386 (1): 30 ...
Invasive ductal carcinoma: 55% of breast cancers Ductal carcinoma in situ: 13% Invasive lobular carcinoma: 5% The vast majority ... Thus invasive ductal carcinoma, the most common form of breast cancer, is adenocarcinoma but does not use the term in its name- ... "The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999-2004". Cancer ... These are divided by total breast cancer incidence (211,300 invasive and 55,700 in situ cases) as reported from Breast Cancer ...
For example, syndecan 1 expression is increased in ductal breast carcinomas and is associated with factors of angiogenesis and ... E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ". ... Breast Cancer Research: BCR. 9 (1): R8. doi:10.1186/bcr1641. Kim, H; Choi, DS; Chang, SJ; Han, JH; Min, CK; Chang, KH; Ryu, HS ... syndecan 1 expression has been linked with low differentiation in squamous cell carcinoma of the head and neck [15]. Syndecan 1 ...
7 in invasive ductal carcinomas of the breast and its clinicopathologic relationships". Breast Cancer Res. 7 (2): R238-47. doi: ...
In a more recent study, the expression of PLEKHA7 protein in high grade ductal breast carcinomas, and lobular breast carcinomas ... "The Expression of the Zonula Adhaerens Protein PLEKHA7 Is Strongly Decreased in High Grade Ductal and Lobular Breast Carcinomas ... "Genetic up-regulation and overexpression of PLEKHA7 differentiates invasive lobular carcinomas from invasive ductal carcinomas ... PLEKHA7 was identified by mass spectrometry in lysates of human intestinal carcinoma (Caco-2) cells in a GST-pull down using N- ...
Breast cancer (invasive ductal). Over-expression. -. Immunohistochemistry. [12]. Breast cancer (BRCA1 deficient). Over- ... "Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas". Int. J. Cancer. 88 (1): 28-36. ... Breast cancer (progesteron receptor negative). Over-expression. -. messenger RNA. [16]. Breast cancer. Under-expression. 30%. ... Several alterations of the Rad51 gene have been associated with an increased risk of developing breast cancer. The breast ...
recurrence invasive ductal carcinoma tmouse After having a lumpectomy, chemo and radiation my wife is 2 1/2 years out from ... 12 Ways to Cut Your Breast Cancer Risk Breast cancer is not an inevitability. From what you eat and drink to how much you ... 17 Deadly Rumors About Breast Cancer From mammograms to personal hygiene, learn the truth about these deadly breast cancer ... Dear tmouse, The treatment of recurrent breast cancer varies depending on where the cancer has recurred. The current standards ...
Diseases : Breast Cancer, Breast Cancer: Ductal Carcinoma In Situ, Breast Cancer: MMTV-Associated, Ductal Carcinoma: Invasive ... Diseases : Breast Cancer, Breast Cancer: Ductal Carcinoma In Situ, Breast Cancer: MMTV-Associated, Ductal Carcinoma: Invasive ... Diseases : Breast Cancer, Breast Cancer: Ductal Carcinoma In Situ, Breast Cancer: Lobular Carcinoma in Situ (LCIS) ... Diseases : Breast Cancer, Breast Cancer: Ductal Carcinoma In Situ, Breast Cancer: Invasive Lobular Carcinoma (ILC) ...
... and Ductal Carcinoma In Situ (DCIS) breast cancers are types that start in the milk ducts. Learn more about how they are ... How Is Ductal Carcinoma in Situ Treated? What Is Ductal Carcinoma?. Ductal carcinoma is a common type of breast cancer that ... What Is Invasive Ductal Carcinoma?. Invasive ductal carcinoma (IDC) accounts for about 80% of all invasive breast cancers in ... What is Ductal Carcinoma in Situ (DCIS)?. Ductal Carcinoma in Situ (DCIS), also known as intraductal carcinoma, accounts for ...
Ductal carcinoma in situ of the breast.. Burstein HJ1, Polyak K, Wong JS, Lester SC, Kaelin CM. ... Ductal carcinoma in situ of the breast. [N Engl J Med. 2004] ... Ductal carcinoma in situ of the breast. [N Engl J Med. 2004] ... Ductal carcinoma in situ of the breast. [N Engl J Med. 2004] ... Ductal carcinoma in situ of the breast. [N Engl J Med. 2004] ... Extramammary recurrence of DCIS after total mastectomy: an iatrogenic displacement following needling procedures? [Breast J. ...
Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast. *Ductal Breast Carcinoma In Situ ... 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ. *Ductal Breast ... Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen. *Breast Cancer ... or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer. *Ductal Breast Carcinoma ...
Also get info for medullary, mucinous, papillary and tubular ductal carcinomas. ... treatment and prognosis for invasive ductal carcinoma-from the Johns Hopkins Breast Center in Baltimore, MD. ... Invasive Ductal Carcinoma (IDC). Invasive ductal carcinoma (IDC), also known as infiltrating ductal carcinoma, is cancer that ... Mucinous Ductal Carcinoma - This occurs when cancer cells within the breast produce mucous, which also contains breast cancer ...
The pathology revealed grade 2-3 invasive ductal carcinoma of the right breast and ductal carcinoma in situ of the left breast ... High-grade ductal carcinoma in situ is incredibly rare in male patients. The prognosis for ductal carcinoma in situ (DCIS) in a ... Case Report: Ductal Carcinoma In Situ in the Male Breast. Joshua Chern, Lydia Liao, Raymond Baraldi, Elizabeth Tinney, Karen ... J. Armstrong, C. Saunders, and C. Metcalf, "Male breast ductal carcinoma in situ," ANZ Journal of Surgery, vol. 73, no. 9, pp. ...
Ductal carcinoma in situ (DCIS) of the breast is a noninvasive carcinoma with a wide spectrum of disease, ranging from low- ... E. B. Claus, M. Stowe, and D. Carter, "Oral contraceptives and the risk of ductal breast carcinoma in situ," Breast Cancer ... I. Jiveliouk, B. Corn, M. Inbar, and O. Merimsky, "Ductal carcinoma in situ of the breast in Israeli women treated by breast- ... "Androgen receptor CAG repeat lengths in ductal carcinoma in situ of breast, longest in apocrine variety," Breast, vol. 9, no. 1 ...
14 Studies found for: Breast Ductal Carcinoma , Antimitotic Agents. Also searched for Ductal breast carcinoma, Antimitotic ... Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1. *Invasive Ductal Breast Carcinoma ... Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer. *Breast ... Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women. *Tubular Breast Cancer ...
The American Cancer Society estimates that more than 62,000 news cases of carcinoma in situ will be diagnosed this year. A ... A common type of carcinoma in situ called DCIS (ductal carcinoma in situ or intraductal carcinoma). ... Ductal carcinoma in situ (or DCIS) refers to the most common type of noninvasive breast cancer in women. In situ, or in place ... The term, ductal carcinoma in situ (DCIS), refers to a family of cancers that occur in the breast ducts. There are two ...
Prognostic classification of breast ductal carcinoma in situ. Lancet. 1995;345:1154-7.CrossRefPubMedGoogle Scholar ... Estrogen receptors in ductal carcinoma in situ of the breast. Am Surg. 1990;56:436-9.PubMedGoogle Scholar ... Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least 2 different lines of genetic evolution. J ... Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res. 2004;10:5160-7.CrossRefPubMedGoogle ...
Reciprocal expression of Bcl-2 and p53 in breast ductal carcinoma.. Lee WY1, Jin YT, Tzeng CC. ... We analysed 101 invasive ductal carcinomas of the breast for the expression of bcl-2, p53, c-erbB-2, estrogen and progesterone ... between bcl-2 and p53 expression and to clarify their roles in apoptosis in different histological graded breast carcinomas. ... Breast Neoplasms/metabolism*. *Breast Neoplasms/pathology. *Carcinoma, Ductal, Breast/metabolism*. *Carcinoma, Ductal, Breast/ ...
... of the breast is the most common precursor to invasive carcinoma (IC), the second-leading cause of death in women in USA. There ... Ductal carcinoma in situ (DCIS) of the breast is the most common precursor to invasive carcinoma (IC), the second-leading cause ... Silverstein MJ (2000) Ductal carcinoma in situ of the breast. Annu Rev Med 51:17-32. doi:10.1146/annurev.med.51.1.17PubMed ... Invasive Breast Cancer Invasive Ductal Carcinoma Cellular Automaton Apoptotic Index Necrotic Core These keywords were added by ...
... of the breast has increased significantly in Japanese women. It comprises 14.1% (172/1216) of all primary breast cancers at our ... The incidence of ductal carcinoma in situ (DCIS) ... Breast Ductal carcinomain situ Atypical ductal hyperplasia ... Silverstein MJ, Poller DN: van Nuys ductal carcinoma in situ classification. In Ductal carcinoma in situ of the breast. Ed by ... Ductal carcinoma in situ and atypical ductal hyperplasia of the breast diagnosed at stereotactic core biopsy.Breast J 7:14-18, ...
A new genetic-based model may explain how a common form of early-stage breast cancer known as ductal carcinoma in situ ... Tags: Bioinformatics, Breast Cancer, Breast Milk, Cancer, Carcinoma, Cell, DNA, DNA Sequencing, Ductal Carcinoma, Ductal ... Study provides insight into how early-stage breast cancer progresses to invasive ductal carcinoma. *Download PDF Copy ... A new genetic-based model may explain how a common form of early-stage breast cancer known as ductal carcinoma in situ (DCIS) ...
PHILADELPHIA - Six factors were associated with invasive recurrence of breast cancer after a diagnosis of ductal carcinoma in ... Six Factors May Predict Invasive Breast Cancer Recurrence after Ductal Carcinoma in Situ Diagnosis. ... Forty studies met the eligibility criteria of including at least ten invasive breast cancer events and at least one year of ... Finally, the researchers performed meta-analyses on all factors associated with the recurrence of invasive breast cancer ...
Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast. *Ductal Breast Carcinoma In Situ ... MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ. *Ductal Breast Carcinoma In Situ ... 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ. *Ductal Breast ... A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS). *Breast ...
... is the most common form of breast cancer. Find out about IDC symptoms, diagnosis and treatment at Breast Cancer Care. ... Invasive ductal breast cancer is the most common type of breast cancer in both women and men and accounts for about 75% of all ... We use the term invasive ductal breast cancer although this type of breast cancer is also known as: ... Try our new Breast Cancer Care app for moving forward after breast cancer ...
Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast.. Bohlke K1, Cramer DW, ... with risk of breast cancer in a study of 94 cases of premenopausal ductal carcinoma in situ and 76 controls. Compared with ... women in the upper two tertiles of IGF-I had an elevated risk for ductal carcinoma in situ. Conversely, compared with women in ... women in the upper two tertiles of IGFBP-3 had a decreased risk for ductal carcinoma in situ. After grouping women on the basis ...
Carcinoma. Breast Neoplasms. Carcinoma in Situ. Carcinoma, Ductal, Breast. Breast Carcinoma In Situ. Carcinoma, Intraductal, ... Breast Diseases. Skin Diseases. Carcinoma, Ductal. Adenocarcinoma. Neoplasms, Ductal, Lobular, and Medullary. Lapatinib. ... Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ. The safety and scientific validity of this ... Ductal Breast Carcinoma In Situ HER2/Neu Positive Other: Laboratory Biomarker Analysis Drug: Lapatinib Ditosylate Other: ...
Our work confirms the existence of distinct subpopulations of DCIS lesions, which will likely have utility in breast cancer ... micrographs of biomarkers whose expression correlates with breast cancer aggressiveness are divided by micrographs of ... Although epidemiological studies propose aggressive and non-aggressive forms of ductal carcinoma in situ (DCIS), they cannot be ... subpopulations of DCIS lesions with ratiometric properties resembling either benign fibroadenoma or invasive carcinoma samples ...
Metaplastic ductal carcinoma of the breast accounts for ,1% of all breast carcinomas. This case, which involved a predominant ... of all breast carcinomas.4. Clinically, metaplastic carcinoma has similar features to those of breast carcinoma in general.2,3, ... No suspicious contralateral breast lesion was identified.. Discussion. Metaplastic ductal carcinoma of the breast is a well- ... Radiological Case: Metaplastic ductal carcinoma of the breast. By David T. Boyd, MD, Pouneh Razavi, MD, Pedro Debrito, MD, ...
Forty-four cases were subclinical mammographically-detected carcinomas revealed by the clusters of m ... The role of axillary lymph node dissection for microinvasive ductal carcinoma in situ of the breast was analyzed in a series of ... Breast Neoplasms / pathology*, surgery. Carcinoma, Ductal, Breast / pathology*, surgery. Female. Humans. Lymph Node Excision*. ... The role of axillary lymph node dissection for microinvasive ductal carcinoma in situ of the breast was analyzed in a series of ...
Breast Cancer Res Treat. 2011 Oct;129(3):929-38. doi: 10.1007/s10549-011-1531-1. Epub 2011 May 3. Research Support, Non-U.S. ... Second events following ductal carcinoma in situ of the breast: a register-based cohort study.. Falk RS1, Hofvind S, Skaane P, ... The incidence of ductal carcinoma in situ (DCIS) of the breast has increased in recent decades, particularly, in counties ... Patients with DCIS have an increased risk of both subsequent breast malignancy and breast cancer death compared with women in ...
Buy Ductal Carcinoma In Situ and Microinvasive/Borderline Breast Cancer by Lisa A. Newman, Jessica M. Bensenhaver from ... Ductal Carcinoma In Situ and Microinvasive/Borderline Breast Cancer (Hardback). Lisa A. Newman (editor), Jessica M. Bensenhaver ... Written by experts in the field, Ductal Carcinoma In Situ and Microinvasive/Borderline Breast Cancer is a comprehensive, state- ... "This is a slim but meaty monograph on ductal carcinoma in situ (DCIS) and microinvasive breast cancer. ... The book is ...
  • 2,3,7 In contrast, the case reported by Evans et al 4 of infiltrating ductal carcinoma with osseous metaplasia is most analogous to ours, as their patient exhibited similar clinical features. (appliedradiology.com)
  • Primary osteogenic sarcoma of the breast is a rare clinical entity with few cases described in the literature. (hindawi.com)
  • In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Ductal Carcinoma in Situ of the Breast. (medifocus.com)
  • These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Ductal Carcinoma in Situ of the Breast. (medifocus.com)
  • We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Ductal Carcinoma in Situ of the Breast every 3 months. (medifocus.com)
  • We performed comparative genomic hybridization (CGH) analysis on 43 grade III invasive ductal breast carcinomas positive for basal cytokeratin 14, as well as 43 grade- and age-matched CK14-negative controls, all with up to 25 years (median, 7 years) of clinical follow-up. (aacrjournals.org)
  • Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, Horton J, Hwang S, Johnson PL, Marinovich ML et al (2016) Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. (springermedizin.de)
  • To assess the clinical, morphological and immunophenotypic characteristics of breast carcinomas showing patterns of mixed epithelial and myoepithelial differentiation. (nih.gov)
  • The reports of 4,271 breast MRIs from eight large scale clinical trials were reviewed in 2006. (wikipedia.org)
  • In May 2016, Dr. Quay and Dr. Shu-Chih Chen, Ph.D. had published the book, "Nipple Aspirate Fluid Exfoliative Cytopathology and Molecular Biomarkers: Current Role in the Management of Breast Health," which describes the status of research and clinical practice involving the Atossa technology. (wikipedia.org)
  • The present study aimed to characterize the immunohistochemical expression of vimentin (VIM), of E-cadherin (CDH1), and of cytokeratin 5 (CK5) in patients with invasive ductal carcinomas (IDCs). (scielo.br)
  • Ductal" means "related to the milk ducts " and "in situ" means "in place. (komen.org)
  • Treatment of mastitis and/or abscess in nonlactating women largely the same as that of lactational mastitis, generally involving antibiotics treatment, possibly surgical intervention by means of fine-needle aspiration and/or incision and drainage and/or interventions on the lactiferous ducts (for details, see also the articles on treatment of mastitis, of breast abscess and of subareolar abscess). (wikipedia.org)
  • The majority of breast diseases either originate from lactiferous ducts or are closely related. (wikipedia.org)
  • We feel that a study of AR CAG repeats in benign apocrine metaplasia, which is always immunohistochemically positive for AR, 5 together with and without cases of apocrine and/or non-apocrine in situ and invasive breast carcinoma, would be very valuable in highlighting the importance of CAG repeats and apocrine differentiation. (bmj.com)
  • There is usually no mitotic activity, and two cells populations (epithelial & myoepithelial) are present, like in benign breast glands. (wikipedia.org)
  • A nipple adenoma is a rare benign tumour of the breast. (wikipedia.org)